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The cholinergic system is one of the most crucial neurotransmitter systems in the 
brain and is implicated in dementia.  The activities of both choline acetyltransferase, 
which catalyzes acetylcholine synthesis, and acetylcholinesterase (AChE), which degrades 
brain acetylcholine, are reported to be decreased in the neocortex and hippocampus in 
Alzheimer’s disease (AD) and Parkinson’s disease with dementia (PDD), and this 
decreased activity correlates with the severity of cognitive impairment.  Moreover, loss of 
cholinergic neurons in the nucleus basalis of Meynert has been reported in the brains of AD 
and PDD patients.  On the basis of these pathological findings, reversible AChE inhibitors 
have been used to potentiate cholinergic neurotransmission, with the aim of improving 
cognitive function.  Currently, several AChE inhibitors are prescribed to patients with 
dementia.  Among them, donepezil hydrochloride has proven effective in ameliorating the 
cognitive impairment of demented patients. 
[5-11C-methoxy]Donepezil ([11C]donepezil) was developed for the in vivo 
visualization of donepezil binding to AChE and cholinergic imaging using positron 
emission tomography (PET)1).  An animal study by Funaki et al.2) and a pilot study by 
Okamura et al.3), which applied [11C]donepezil-PET to AD patients, showed that 
[11C]donepezil holds promise as a potential agent for imaging AChE in vivo using PET.  
To exploit the use of [11C]donepezil-PET in clinical research, the kinetic analysis of 
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[11C]donepezil was established using dynamic 60-min PET scans acquired after intravenous 
injection of [11C]donepezil in 6 healthy subjects3). 
Subsequently, we applied donepezil-PET imaging to PDD patients.  Twelve 
patients with PDD (9 men, 3 women; mean age ± SD, 69.8 ± 6.4 years) and 13 healthy 
control subjects matched for age, sex, and education (10 men, 3 women; mean age ± SD, 
69.5±6.7 years) were enrolled.  The patients met the diagnosis of PD according to the 
diagnostic criteria of the UK PD Society Brain Bank, based on clinical, laboratory, and 
radiological findings.  To select subjects with dementia, patients with a score of 1 or above 
on at least one of the sub-items of the Clinical Dementia Rating (CDR) were included in 
this study.  For patients with Parkinson’s disease with dementia, daily administration of 
donepezil was started after [11C]donepezil-PET imaging and continued for 3 months.  At 
baseline and after 3 months of donepezil therapy, cognitive function was evaluated.  The 
Ethics Committee of Tohoku University School of Medicine approved the study protocol, 
and written informed consent was obtained from all healthy subjects and from patients or 
their family members.  
Radiosynthesis of the [11C]donepezil and the PET procedures used are described 
elsewhere1,3).  The acquired PET and metabolite-corrected blood data were analyzed using 
the software PMOD (PMOD Technologies) and parametric 3D maps of total distribution 
volume (tDV) in the brain were generated using the classical Logan plot.  Images were 
analyzed using SPM8 (Wellcome Department of Cognitive Neurology) and ImageJ 1.42q 
(National Institutes of Health, Bethesda, MD). 
 The tDVs of the total cerebral cortices were estimated using a semi-automatic 
method.  Axial 3D magnetic resonance images were obtained for anatomical reference, 
which were segmented into gray and white matter using the prior probability templates of 
SPM8.  The total cerebral cortices in the probability maps of the gray matter were 
extracted by tracing with a manually driven mouse cursor on ImageJ and then co-registered 
with the tDV images.  The co-registered images were used as a mask of the cerebral 
cortices, and were projected onto the tDV images of each subject to extract the cerebral 
cortices.  Finally, the mean tDV value of the cerebral cortices was calculated.  A 
two-tailed t-test was used for group comparison with statistical significance set at p < 0.05. 
 A between-group comparison examining the difference in tDV values at voxel level 
was performed using analysis of covariance (ANCOVA) with the software SPM8, with sex, 
age, and education as covariates in an explorative analysis covering the whole brain without 
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any a-priori hypothesis. Statistical significance was set at p < 0.005 without correction for 
multiple comparisons, and cluster extent threshold was 100 voxels. 
 The mean tDVs of the cerebral cortices in the PDD group were significantly lower, 
showing a mean decrease rate of 22.7%, than those of the control group (PDD, 7.9±2.2; NC, 
10.2± 2.7).  In the SPM analysis, the PDD group exhibited a widespread tDV reduction as 
compared with the control group (Fig. 1).  The mean total distribution volume of the 
patients with PDD was significantly correlated with improvement of visuoperceptual 
function after 3 months of donepezil therapy (Table 1). 
 The use of [11C]donepezil-PET in the present clinical study of PDD revealed that 
AChE in the cerebral cortices was decreased.  Among previous studies of cholinergic PET 
imaging utilizing radiolabeled acetylcholine analogues, such as [11C]PMP, Hilker et al4). 
and Bohnen et al5). found a 20.0-29.7% and a 10.7-12.9% reduction in cortical 
acetylcholinesterase activity in Parkinson’s disease with and without dementia, respectively, 
compared with normal subjects.  The reduction rate of the mean tDV value of the cerebral 
cortices in the PDD group in the present study was similar to that of cortical 
acetylcholinesterase activity reported in these previous studies.  Voxel-by-voxel analysis 
using SPM8 revealed a global reduction in acetylcholinesterase density in the brains of 
PDD patients, similar to the results of previous studies.  The results also suggested that 
donepezil therapy is more effective in patients with less decrease in acetylcholinesterase, 
which indicates relative preservation of the cholinergic system. 
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Table 1.  Correlation matrix contrasting mean distribution volume of the cerebral cortices against the 
change in the cognitive tests after 3-month donepezil therapy. 
 
    change   
      digit span   
  MMSE  fluency TMT-A 
      (WAIS-R)   
 correlation coefficient   -0.207     -0.036 0.165 0.116 
 P 0.593      0.928 0.672 0.827 
      
    change   
  recall task    recognition visuoperceptual  
     NPI 
  (ADAS)   TASK (ADAS) test  
 correlation coefficient   -0.406      0.207 0.837 -0.091 
 P 0.278      0.594 0.005  0.817 
 
MMSE=MIni-MentalState Fxamination; WAIS-R=Wechsler Adalt Intelligence Scale-Revised; 
TMT-A=Trail-Making Tesst-A: ADAS=Alzhheimer's Disease Assessment Scale;NPI= 
Neuropsychiatric Inventory 
 
 
 
 
 
 
Figure 1.  Statistical parametric maps of a significant decrease in [11C]donepezil distribution volume in the 
PDD group as compared with the normal control group (puncorrected <0.005). 
 
